NATCO launches generic Pomalidomide Capsules in Canada

NATCO Pharma Limited (NSE: NATCOPHARM; BSE: 524816) announces launch of Pomalidomide Capsules in Canada, the first generic alternative to POMALYST® brand in the country approved by Health Canada. Pomalidomide is used in combination with Dexamethasone and Bortezomib for the treatment of adult patients with multiple myeloma. Multiple myeloma, commonly referred to as myeloma, is a cancer of plasma cells. It is the second most common form of blood cancer in Canada with about 8,000 Canadians living with myeloma.

Natco launched pomalidomide under their brand NAT-POMALIDOMIDE in strengths of 1 mg, 2 mg, 3 mg and 4 mg capsules and available through the RevAid® risk management platform. This launch reflects Natco's continued investment in Canada to expand portfolio of high-quality generic medicines at affordable prices.

RevAid® and POMALYST are trademarks of Celgene Corporation.

Shares of Natco Pharma Limited was last trading in BSE at Rs. 538.10 as compared to the previous close of Rs. 543.10. The total number of shares traded during the day was 8204 in over 1212 trades.

The stock hit an intraday high of Rs. 549.45 and intraday low of 536.50. The net turnover during the day was Rs. 4430104.00.

Source : Equity Bulls

Keywords

NatcoPharma INE987B01026 Pharmaceuticals PomalidomideCapsules Canada